Cargando…
Pathological pseudoprogression to anti-PD-1 inhibitor in metastatic periampullary carcinoma: Case report
Pseudoprogression has been deemed as a rare clinical phenomenon during the treatment of immune checkpoint inhibitors in patients with advanced cancers, especially in periampullary carcinoma, however, leaving potential molecular mechanism remain unknown. PATIENT CONCERNS: Regular examination after ra...
Autores principales: | Wang, Junhui, Wang, Yan, Che, Xiaoling |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875975/ https://www.ncbi.nlm.nih.gov/pubmed/36705379 http://dx.doi.org/10.1097/MD.0000000000032644 |
Ejemplares similares
-
Apatinib combined with temozolomide treatment for pseudoprogression in glioblastoma: A case report
por: Zhao, Mingming, et al.
Publicado: (2022) -
Not only for melanoma. Subcutaneous pseudoprogression in lung squamous-cell carcinoma treated with nivolumab: A case report
por: Sarfaty, Michal, et al.
Publicado: (2017) -
Pseudoprogression in the era of immunotherapy-based strategies for recurrent head and neck squamous cell carcinoma achieving complete response: A case report
por: Zhou, Jiawei, et al.
Publicado: (2023) -
Influence of non-jaundice stage at diagnosis on clinicopathological features and long-term survival of patients with periampullary carcinomas
por: Peng, Xiaoqian, et al.
Publicado: (2019) -
Remarkable response to anti-PD1 immunotherapy in refractory metastatic high-grade myxofibrosarcoma patient: A case report
por: Luo, Yi, et al.
Publicado: (2021)